Radiolabeled antibodies for treatment of tumors

Details Radiolabeled antibodies for treatment of tumors Radiolabeled antibodies for treatment of tumors

2008-07-22

2008-07-22

Fetterolf, Brandon J (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C424S001490, C424S130100, C424S155100

Reexamination Certificate

active

10775869

ABSTRACT:
This invention provides methods for imaging and/or treating a tumor in a subject which comprise administering to the subject an amount of a radiolabeled antibody effective to image and/or treat the tumor, where the radiolabeled antibody binds to a cellular component released by dying tumor cells. This invention also provides methods for imaging and/or treating melanin-containing melanomas in a subject which comprise administering to the subject an amount of a radiolabeled anti-melanin antibody effective to image and/or treat the melanoma. The invention also provides compositions and methods of making compositions comprising radiolabeled antibodies for imaging and treating tumors, including melanin-containing melanomas.

REFERENCES:
patent: 4444744 (1984-04-01), Goldenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 5047227 (1991-09-01), Rodwell et al.
patent: 5102990 (1992-04-01), Rhodes
patent: 5332567 (1994-07-01), Goldenberg
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6319500 (2001-11-01), Goldenberg
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6395276 (2002-05-01), Rybak et al.
patent: 6458933 (2002-10-01), Hansen
patent: 6548275 (2003-04-01), Goldenberg
patent: 6653104 (2003-11-01), Goldenberg
patent: 6667024 (2003-12-01), Goldenberg et al.
patent: 2003/0198595 (2003-10-01), Goldenberg et al.
patent: 2006/0039858 (2006-02-01), Dadachova et al.
Mason et al. (Cancer Research 1954; 14; 648-650).
Wilder et al. (J. Clin. Oncol. 1996; 14: 1383-1400).
Erdi et al. (Phys. Med. Biol. 1996; 41: 2009-2026).
Chatel et al. (Eur. J. Nucl. Med. 1992; 19: 205-213).
[Fundamental Immunology 242 (William E. Paul, M.D. ed., 3rd ed. 1993)]—292-295.
Wilder et al. (J. Clin. Oncol. 1996; 14: 1383-1400).
Erdi et al. (Phys. Med. Biol. 1996; 41: 2009-20026).
Milenic et al. (Nature Rev. Drug Discovery 3: 488-498, 2004).
Dadachova et al. (“Radioimmunotherapy of Pigmented Melanoma with Melanin-Targeting Antibody,” In Program of Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates, Oct. 22, 2002, Abstract, P-08).
Kobayashi et al. (Cancer Research 1996; 56: 3788-3795).
Allen BJ, Rizvi SM, Tian Z., entitled “Preclinical targeted alpha therapy for subcutaneous melanoma,” Melanoma Res 11: 175-182, 2001.
Charlton DE., entitled “The survival of monolayers of cells growing in clusters irradiated by 211-AT appended to the cell surfaces,” Radiat Res. 151: 750-753, 1999.
Chen, J, Giblin MF, Wang N, Jurisson SS, Quinn TP, entitled In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol. Aug. 1999; 26(6): 687-93.
Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP, Jurisson SS, entitled “Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111) In-labeled DOTA- conjugated rhenium-cyclized alpha-MSH analogues,” J Med Chem. Jul. 4, 2002:45(14): 3048-56.
Hill, HZ, entitled “The function of melanin or six blind people examine an elephant,” Bioessays 14: 49-56, 1992.
Kinnaert E, Morandini R, Simon S, Hill HZ, Ghanem G, Van Houtte P, entitled “The degree of pigmentation modulates the radiosensitivity of human melanoma cells,” Radiat Res. 154: 497-502, 2000.
Kwok CS, Civici A, MacGregor WD, Unger MW, entitled “Optimization of radioimmunotherapy using human malignant melanoma mutlicell spheroids as a model,” Cancer Res. 49: 3276-3281, 1989.
Lindmo T, Boven E, Mithcell JB, Morstyn G, Bunn PA Jr., entitled “Specific Killing of human melanoma cells by 125I- labeled 9.2.27 monoclonal antibody,” Cancer Res. 45: 5080-5087, 1985.
Ong GL, Elsamra SE, Goldenberg DM, Mattes MJ, entitled Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res 7: 192-201, 2001.
Rofstad, EK, entitled “Radiation biology of malignant melanoma,” Acta Radiol. Oncol. 25 1-10, 1986.
Dadachova, E et al., entitled “Melanin-targting antibody as a potential agent for radioimmunotherapy of melanoma,” World Journal of Nuclear Medicine, vol. 1, Supplement 2, Sep. 2002, S275, Abstract.
Dadachova, E et al., entitled “Radioimmunotherapy of Pigmented Melanoma with Melanin-Targeting Antibody,” In Program of Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates, Oct. 2002, Abstract, P-08.
Rosas et al., “Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal cryptococcus neoformans infection.” Infection and Immunity, 3410-3412, May 2001.

Affiliated with

Also associated with

Rating

Radiolabeled antibodies for treatment of tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Radiolabeled antibodies for treatment of tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiolabeled antibodies for treatment of tumors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3945768